Shopping Cart

Your shopping cart is currently empty

(Z)-Orantinib

Name: (Z)-Orantinib
Brand: TargetMol
SKU: T9684
Price: 35 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T9684Cas No. 210644-62-5

Alias (Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668

(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.

(Z)-Orantinib

🥰Excellent

Purity: 98.05%

Catalog No. T9684Alias (Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668Cas No. 210644-62-5

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
5 mg	$35	-	In Stock
1 mL x 10 mM (in DMSO)	$52	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.05%

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.
Targets&IC50	FLK1/KDR:2.1 μM, FGFR1:1.2 μM, PDGFRβ:0.008 μM
In vitro	(Z)-Orantinib (5-15 minutes) inhibits Flk-1 transphosphorylation, FGFR1 transphosphorylation, and PDGFR autophosphorylation, with Ki values of 2.1 μM, 1.2 μM, and 0.008 μM, respectively [1]. (Z)-Orantinib (0.03-10 μM, 60 minutes) suppresses the increase in KDR tyrosine phosphorylation levels induced by VEGF in HUVECs [1]. (Z)-Orantinib shows dose-dependent inhibitory effects on the mitogenic activity of VEGF- and FGF-induced HUVECs, with IC50 values of 0.34 μM and 9.6 μM, respectively [1].
In vivo	(Z)-Orantinib (4-200 mg/kg, orally administered for 21 days) demonstrated dose-dependent inhibitory effects on the growth of A431 tumors in nude mice [1]. (Z)-Orantinib (75 mg/kg, administered intraperitoneally for 22 days) demonstrated significant inhibition of tumor angiogenesis and vascular formation in mice [1]. (Z)-Orantinib (200 mg/kg, orally administered for 11-27 days) significantly induced regression of established large A431 parazacco spilurus subsp. spilurus xenograft tumors in nude mice [1].
Synonyms	(Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668

Chemical Properties

Molecular Weight	310.35
Formula	C₁₈H₁₈N₂O₃
Cas No.	210644-62-5
Smiles	C(=C\1/C=2C(NC1=O)=CC=CC2)\C3=C(C)C(CCC(O)=O)=C(C)N3
Color	Orange
Appearance	Solid

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 40 mg/mL (128.89 mM), Sonication is recommeded.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.2222 mL	16.1108 mL	32.2217 mL	161.1084 mL
5 mM	0.6444 mL	3.2222 mL	6.4443 mL	32.2217 mL
10 mM	0.3222 mL	1.6111 mL	3.2222 mL	16.1108 mL
20 mM	0.1611 mL	0.8055 mL	1.6111 mL	8.0554 mL
50 mM	0.0644 mL	0.3222 mL	0.6444 mL	3.2222 mL
100 mM	0.0322 mL	0.1611 mL	0.3222 mL	1.6111 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH₂O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH₂O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.

All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc